Medicus Pharma Ltd. announced the appointment of Carolyn Bonner as Chief Financial Officer in addition to her role as President.
Bonner succeeds Jim Quinlan, who resigned for health reasons after taking medical leave in September 2025.
This move aims to enhance continuity, stability, and operational integration at Medicus.
Proven Leadership in Healthcare
Carolyn Bonner brings nearly 20 years of experience in healthcare and life sciences, with a strong track record in executive leadership and corporate development.
Expanded Responsibilities
As President and CFO, Bonner will oversee financial reporting, capital markets strategy, and lead strategic planning for Medicus Pharma Ltd.
Clinical Development Progress
Medicus is making significant progress in its clinical development programs, with positive feedback from the FDA and ongoing studies for BCC treatment.
- Carolyn Bonner's appointment brings alignment in corporate objectives and leadership continuity at Medicus Pharma Ltd.
- The positive trending interim analysis for SKNJCT-003 demonstrates promising results in treating basal cell carcinoma, showing over 60% clinical clearance.
The appointment of Carolyn Bonner as CFO and President underscores Medicus's commitment to strong leadership and strategic growth in the healthcare sector.